Amgen – Hot or Not

PUBLISHED: Thu, 28 Sep 2017 04:53:41 GMT
Share


Amgen (Nasdaq:AMGN) is a biotechnology company with blockbuster products like Neupogen, Enbrel and Repatha. It has a market cap of $135.4 bn, a price to earnings ratio of 16.88 and a dividend yield of 2.48 per cent. Guest Nesan Nair, Sasfin Securities and resident expert Paul Theron from Vestact decide whether Amgen is hot or not.

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.